CEBP Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poole, E. M.
Right arrow Articles by Ulrich, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poole, E. M.
Right arrow Articles by Ulrich, C. M.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 502-508, March 2006
© 2006 American Association for Cancer Research

Prostacyclin Synthase and Arachidonate 5-Lipoxygenase Polymorphisms and Risk of Colorectal Polyps

Elizabeth M. Poole1,2, Jeannette Bigler1, John Whitton1, Justin G. Sibert1, John D. Potter1,2 and Cornelia M. Ulrich1,2

1 Fred Hutchinson Cancer Research Center and 2 Department of Epidemiology, University of Washington, Seattle, Washington

Requests for reprints: Cornelia Ulrich, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-B402, Seattle, WA 98109-1024. Phone: 206-667-7617; Fax: 206-667-7850. E-mail: nulrich{at}fhcrc.org


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Prostacyclin synthase (PGIS) and arachidonate 5-lipoxygenase (ALOX5) are enzymes relevant to prostaglandin and leukotriene synthesis, both important pathways for colon cancer risk. We hypothesized that genetic variation altering the function of these enzymes would modify risk of colorectal polyps. In a Minnesota-based case-control study of adenomatous (n = 517) or hyperplastic (n = 192) polyps versus polyp-free controls (n = 618), we investigated the role of promoter repeat polymorphisms in PGIS and ALOX5 as well as ALOX5 –1700 G>A. Having fewer than six repeats on both PGIS alleles (<6R/<6R) was associated with an increased risk of adenomas compared with the 6R/6R (wild-type) genotype (OR, 1.90; 95% CI, 1.09-3.30). Having more repeats (>6R/≥6R) reduced risk (OR, 0.73; 95% CI, 0.40-1.35; Ptrend = 0.03). In allele-based analyses, fewer repeats were associated with a modestly increased risk of adenomas and perhaps hyperplastic polyps. There were no risk differences for either the ALOX5 VNTR or –1700 G>A polymorphisms. Associations with regular use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) differed by PGIS genotype. Among individuals with at least one wild-type allele, NSAID use was associated with a decreased risk; however, those with fewer PGIS repeats (<6R/<6R) did not benefit (Pinteraction = 0.06). There was also evidence of an interaction between the COX-2 –765 G>C and ALOX5 –1700 G>A genotypes (Pinteraction = 0.07). The PGIS promoter polymorphism may affect risk of colorectal polyps and modify the effects of NSAID use on polyp risk. A more comprehensive investigation of genetic variability in prostaglandin synthesis in relation to risk of colorectal neoplasia and NSAID pharmacogenetics is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(3):502–8)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Arachidonic acid is metabolized by the colon through two main pathways, the prostaglandin and leukotriene cascades (see Fig. 1; ref. 1). Prostaglandins are produced by most cells in the body and participate in inflammatory responses and other cellular activities (2). The central enzymes in the prostaglandin pathway are cyclooxygenases 1 and 2 (COX-1 and COX-2), which form prostaglandin H2, the precursor of all other prostaglandins (2).


Figure 1
View larger version (28K):
[in this window]
[in a new window]
  		Figure 1. ALOX5 and PGIS in the prostaglandin and eicosanoid synthesis pathway.

 
Prostaglandins have been found to be up-regulated in colon cancer (3-5) and genetic polymorphisms in both COX-1 and COX-2 have previously been associated with colon neoplasia risk by our group and others (6-10). COX-1 and COX-2 are the primary targets of nonsteroidal anti-inflammatory drugs (NSAIDs; ref. 11), which are known to prevent colorectal neoplasia (12-15).

Although COX-1 and COX-2 have been the focus of much research, the effects of genetic variants in other enzymes in the prostaglandin pathway have not been as thoroughly examined. One of these enzymes, prostaglandin I2 synthase (prostacyclin synthase or PGIS), acts downstream of COX-1 and COX-2 to catalyze the formation of prostaglandin H2 into prostaglandin I2 (or prostacyclin; see Fig. 1). Prostacyclin may play a number of roles in preventing cancer, including suppression of inflammation and cell proliferation, promotion of apoptosis, prevention of metastasis, and reduced growth of established metastases (16-19). The cardiovascular toxicity caused by COX-2-specific inhibitors may be in part due to reduced production of prostacyclin, which has antithrombotic activity (20). As the enzyme responsible for the production of prostacyclin, PGIS may be important in cancer prevention. PGIS is expressed in a wide array of tissues, including ovaries, heart, skeletal muscle, lung, and prostate, suggesting that PGIS has a variety of functions (21).

Prostacyclin levels can be reduced in colorectal cancer (4). A study of murine colon adenocarcinomas reported reduced tumor incidence and burden in transgenic mice engineered to overexpress PGIS (22). In vitro studies of human colon cancer cell lines have shown evidence that increased levels of prostacyclin may prevent metastases (23). In addition, several studies have examined the role of PGIS in lung cancer with comparable results, reporting reduced tumor incidence and burden among mice overexpressing PGIS (24, 25) and no expression of both PGIS or prostacyclin in human lung tumors (26).

Another major pathway for the metabolism of arachidonic acid is via its conversion by lipoxygenases [5-lipoxygenase (ALOX5), ALOX12, and ALOX15] to other signaling molecules, specifically to leukotrienes via ALOX5, to 12-hydroperoxyeicosatetrenoic (12-HPETE) via ALOX12, and to 15-HPETE via ALOX15. ALOX5 and ALOX12 have been described as procarcinogenic lipoxygenases and are both up-regulated in several cancer types whereas ALOX15 seems to be anticarcinogenic, possibly through its role in the metabolism of linoleic acid or through inhibition of the products of the ALOX5 and ALOX12 cascades (27).

Arachidonate 5-lipoxygenase (ALOX5) is a dual-function protein that catalyzes the oxygenation of arachidonate to 5-HPETE and its subsequent conversion to leukotriene A4 (28). Downstream products of ALOX5 have been shown to enhance cell proliferation and increase cell survival (29). In addition, ALOX5 is up-regulated in colon cancer (27, 30), as well as several other cancer types, including esophageal (31), breast (32), prostate (33), and pancreatic cancers (34). ALOX5 has also been shown to play a role in angiogenesis in mouse models of cigarette smoke–induced inflammatory tumorigenesis (35).

Genetic polymorphisms in both PGIS and ALOX5 have been identified. A 9-base variable number of tandem repeat (VNTR) polymorphism [–3(CCAGCCCCG)3-8] has been identified in the promoter region of PGIS (originally designated CYP8A1; refs. 36, 37). In luciferase assays, alleles with fewer repeats (3R, 4R, or 5R) were associated with reduced promoter activity compared with wild-type (6R)—the 4R allele had 3-fold lower promoter activity and the 5R allele had 2-fold lower activity compared with 6R in three cell lines exposed to interleukin-6 stimulation (36, 37). The PGIS VNTR polymorphism has been associated with cerebral infarction and hypertension (36, 38).

In the promoter region of ALOX5, a 6-base VNTR polymorphism [–176(GGGCGG)2-8] and a single-nucleotide polymorphism (–1700 G>A) have been identified (39). In promoter assays in two cell lines, the 3R allele of the VNTR polymorphism was associated with a 40% to 78% reduction in activity compared with wild-type (5R). The ALOX5 4R allele was associated with a 30% reduction whereas the 6R allele was associated with 20% lower activity in one cell line and a 60% increase of activity in another (39, 40). The effects of the ALOX5 –1700 G>A polymorphism are unclear. The ALOX5 VNTR polymorphism has not yet been investigated in relation to colorectal cancer whereas the –1700 G>A polymorphism has previously been associated with a decreased risk of colon cancer (8).

Due to the associations of both PGIS and ALOX5 with various types of cancer, we hypothesized that genetic variation in PGIS and ALOX5 could alter the risk of colorectal neoplasms. We investigated associations between the PGIS VNTR polymorphism and the two ALOX5 polymorphisms and risk of colorectal adenomatous and hyperplastic polyps. We further investigated possible interactions with aspirin or other NSAID use and polymorphisms in COX-1, COX-2, or TGF-ß1 (an inducer of COX-2; ref. 41).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Subjects
Participant recruitment for the Minnesota case-control study has previously been described (42). Briefly, cases with colorectal adenomatous and/or hyperplastic polyps and polyp-free controls were recruited through a large multiclinic private gastroenterology practice in metropolitan Minneapolis. Patients of ages 30 to 70 years, who were scheduled to undergo colonoscopy between April 1991 and April 1994, were enrolled before colonoscopy to blind patients and recruiters to the final diagnosis. The internal review boards of the University of Minnesota and each endoscopy site approved this study. Written informed consent was obtained from all participants.

Eligible participants were Twin Cities metropolitan area residents, English-speaking, had no known genetic syndrome associated with predisposition to colonic neoplasia, and had no individual history of cancer (except nonmelanoma skin cancer) or inflammatory bowel disease. Cases had a first diagnosis of colon or rectal adenomatous (n = 521) or hyperplastic polyp (n = 194) at the time of colonoscopy whereas controls were polyp-free (n = 621). Patients for whom colonoscopy did not reach the cecum were excluded. Removed polyps were examined histologically according to standard diagnostic criteria (43).

Information on use of aspirin and other NSAIDs, lifestyle factors and diet, demographics, anthropometry, and medical information, including family history of cancer and polyps, was obtained by questionnaire. The participation rate for all colonoscoped patients was 68%.

Genotyping
Genomic DNA was extracted from peripheral WBC using the Puregene kit (Gentra Systems, Minneapolis, MN). PGIS genotyping was done at the Core Laboratory of the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center (J.B.). The promoter repeat polymorphisms of ALOX5 and PGIS were genotyped using GeneScan (Applied Biosystems, Foster City, CA) assays and the ALOX5 –1700 G>A polymorphism was genotyped by TaqMan assay (Applied Biosystems). The ALOX5 VNTR reactions consisted of 40 ng genomic template DNA, 1.5 mmol/L MgCl2, 1x PCR Gold Buffer (Applied Biosystems), 0.5 units of Amplitaq Gold Polymerase (Applied Biosystems), 200 nmol/L each of oligonucleotide primers ALOX5sp1-F 5'-6FAM-AGGAACAGACACCTCGCTGAGGAGAG-3' and ALOX5sp1-R 5'-GAGCAGCGAGCGCCGGGAGCCTCGGC-3' (ref. 44; Applied Biosystems), 150 µmol/L each of dATP, dCTP, and dTTP, 75 µmol/L each of dGTP and 7-deaza-2'-dGTP (Roche Diagnostics GmbH, Mannheim, Germany), and 8% (v/v) DMSO (Sigma, St. Louis, MO) in 20 µL. Cycling was at 94°C for 10 minutes, followed by 30 cycles of 94°C for 30 seconds, 62°C for 45 seconds, 72°C for 1 minute, and finally 72°C for 5 minutes. The observed amplicon lengths ranged from 257 bp (2 repeats) to 293 bp (8 repeats). The PGIS 9-base promoter repeat reactions consisted of 40 ng genomic template DNA, 1.2 mmol/L MgCl2, 1x PCR Gold Buffer (Applied Biosystems), 0.5 units of Amplitaq Gold Polymerase (Applied Biosystems), 200 nmol/L each of oligonucleotide primers PGIS-F 5'-6FAM-CACATTTTCCATCAGGCCTGAGCTG-3' and PGIS-R 5'-GGGATACTGGAGCGGGACTCGG-3' (Applied Biosystems), 150 µmol/L each of dATP, dCTP, and dTTP, 75 µmol/L each of dGTP and 7-deaza-2'-dGTP (Roche), 2% (v/v) formamide (Applied Biosystems), and 6% (v/v) DMSO (Sigma) in 20 µL. Cycling was at 94°C for 15 minutes, followed by 35 cycles of 94°C for 30 seconds, 64°C for 45 seconds, 72°C for 1 minute, and finally 72°C for 5 minutes. The observed amplicon lengths ranged from 411 bp (3 repeats) to 456 bp (8 repeats). Amplicons from both reactions were combined and run on the ABI 3100 Genetic Analyzer. Data were analyzed with Genotyper software version 3.7 and manually reviewed. The ALOX5 –1700 G>A polymorphism was genotyped using a TaqMan assay in which 3.75 ng of genomic DNA were amplified with a TaqMan Core Reagent Kit with AmpErase UNG (Applied Biosystems). The 20-µL reactions were 5.0 mmol/L MgCl2, 100 nmol/L each of oligonucleotide primers ALOX5 –1700F 5'-CCCCAAATTGATCTACAGCTTCA-3' and ALOX5 –1700R 5'-TTGTCCATGCATCATTTGTTGA-3', and 200 nmol/L each of antisense oligonucleotide probes with nonfluorescent MGB quencher, ALOX5 –1700G 5'VIC-TAGTCCACTGATCTGTAAT-3' and ALOX5 –1700A 5'-6FAM-CTAGTCCATTGATCTGTAA-3', and a 360-bp amplicon was created. Cycling consisted of 2-minute incubation at 50°C, 10-minute denaturation at 95°C, and 45 cycles of 95°C for 15 seconds and 60°C for 3 minutes. All cyclings were done on Perkin-Elmer Gene Amp PCR System 9700. All results were repeated for 94 randomly selected samples for quality control, with no discrepancies. All results were confirmed in a separate previously described population (45).

Statistical Data Analysis
Logistic regression analysis was used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (95% CI); PGIS and ALOX5 status, both specific genotypes and alleles (number of repeats on one allele), among cases with adenomatous or hyperplastic polyps was compared with polyp-free controls. Multivariate adjustment for previously identified risk factors (age, sex, body mass index, dietary intakes of fiber, alcohol, energy, postmenopausal hormone use, and smoking) was used largely because of some confounding in the stratified analyses. Possible effect modification by NSAID use or polymorphisms in COX-1, COX-2, or TGF-ß1 was evaluated by including the respective multiplicative interaction term in the logistic regression models. All statistical tests were two sided and analyses were done with SAS 9.1 (SAS Institute, Cary, NC).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Characteristics of the study population have previously been described (42, 46, 47). Briefly, adenoma cases were older than those with hyperplastic polyps and polyp-free controls and were more likely to be male. Regular use of aspirin or other NSAIDs was somewhat more common among controls compared with both case groups. To evaluate risk based on specific genotypes present in the population, the PGIS and ALOX5 repeat polymorphism genotypes were grouped according to putative phenotype (amount of gene expression relative to wild-type). Genotype and allele frequencies among case groups and controls are listed in Table 1; phenotypic groupings are shown in Table 2. All polymorphisms were in Hardy-Weinberg equilibrium in both cases and controls.


View this table:
[in this window]
[in a new window]
  		Table 1. Genotype and allele frequencies among adenoma cases, hyperplastic polyp cases, and controls

 

View this table:
[in this window]
[in a new window]
  		Table 2. Association between PGIS and ALOX5 polymorphisms and risk of adenomatous and hyperplastic polyps

 
ORs for the PGIS and ALOX5 genotypes and alleles are shown in Table 2. For the PGIS polymorphism, having fewer than 6 repeats on both alleles (<6R/<6R) was associated with an increased risk of adenomas compared with the 6R/6R (wild-type) genotype (OR, 1.90; 95% CI, 1.09-3.30). Although not statistically significant, this pattern of an increased risk with fewer repeats was also seen for hyperplastic polyps (OR, 1.86; 95% CI, 0.91-3.81). Having more repeats [>6R/≥6R, i.e., at least 6 (= wild-type) repeats on one allele and more than 6 on the other] was associated with a nonsignificantly decreased risk of adenomas (OR, 0.73; 95% CI, 0.40-1.35). There was a statistically significant trend of decreasing adenoma risk with increasing number of PGIS repeats (P = 0.03). Associations in the allele-based analysis were more modest, although the trends were similar (Ptrend = 0.04), such that the PGIS allele with 4 repeats was associated with an increased adenoma risk (OR, 1.30; 95% CI, 1.01-1.68). Similar results were observed for hyperplastic polyps.

There were no significant differences in polyp risk for either of the ALOX5 polymorphisms. For the ALOX5 VNTR polymorphism, carrying an allele with any number of repeats other than wild-type (5 repeats) was associated with decreased risk of both adenomas and hyperplastic polyps, but these results were not statistically significant and no clear trends were observed (Table 2).

Regular aspirin or other NSAID use (>1/wk for at least 1 year) has previously been associated with a decreased risk of adenomas in this study population (for aspirin, OR, 0.63; 95% CI, 0.44-0.90; for other NSAIDs, OR, 0.50; 95% CI, 0.31-0.82; ref. 47). Because the primary targets of NSAIDs are the COX-1 and COX-2 enzymes in the initial synthesis of prostaglandins from arachidonic acid, we evaluated whether these protective associations were altered by PGIS or ALOX5 genotype.

The associations with regular use of aspirin or other NSAIDs differed by PGIS genotype (Fig. 2; Table 3). Among individuals with at least one wild-type allele, NSAID use was associated with a decreased risk; in contrast, among those with fewer repeats (<6R/<6R), there was no reduction in risk (Pinteraction = 0.06; Table 3). In a direct comparison (i.e., excluding all other genotype groups) of individuals with fewer repeats on both alleles (<6R/<6R; lower PGIS expression) compared with those who were wild-type (6R/6R), there was a statistically significant interaction (P = 0.03), suggesting that individuals with reduced PGIS expression may not benefit from NSAID use. There was no statistically significant interaction between either of the ALOX5 polymorphisms and regular NSAID use.


Figure 2
View larger version (39K):
[in this window]
[in a new window]
  		Figure 2. Risk of colorectal adenomas by PGIS VNTR genotype and NSAID use.

 

View this table:
[in this window]
[in a new window]
  		Table 3. Association between PGIS genotype and risk of adenomatous polyps, stratified by NSAID use

 
To elucidate the combined effects of genetic variability in the prostaglandin synthesis pathway (see Fig. 1), we investigated gene-gene interactions between PGIS and ALOX5 and polymorphisms in COX-1 (R8W, P17L, L15-L16del, and L237M), COX-2 (–765 G>C), and TGF-ß1 (L10P). There is evidence for the functional relevance of these polymorphisms (48-51) and we have previously shown that they can alter risk of polyps or modify NSAID associations (6, 7, 52). No statistically significant interactions between PGIS or ALOX5 and TGF-ß1 or COX-1 were observed, nor was there evidence for an interaction between PGIS and COX-2. Due to the low allele frequencies, in particular for COX-1 polymorphisms, our statistical power was limited. However, there was a suggestion of an interaction between the COX-2 promoter polymorphism (–765 G>C) and ALOX5 –1700 G>A (Table 4). Among those who had the wild-type ALOX5 genotype, variant COX-2 alleles were associated with a decrease in adenoma risk; among those with ALOX5 GA or AA genotype, adenoma risk increased with variant COX-2 alleles (Pinteraction = 0.07).


View this table:
[in this window]
[in a new window]
  		Table 4. ALOX5 genotype, COX-2 –765 G>C genotype, and risk of adenomatous polyps

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This study illustrates that genetic variability in enzymes relevant to the formation of prostaglandins and other eicosanoids can affect the risk of colorectal neoplasia and be potentially relevant for the pharmacogenetics of NSAIDs. We hypothesized that individuals with fewer PGIS repeats would be at increased risk of colorectal polyps given that increasing numbers of repeats have been associated with increasing PGIS promoter activity. As discussed previously, mouse genetic and human association studies suggest a cancer-preventive role of prostacyclin (36-38). Our findings, showing an association between fewer PGIS repeats and polyp risk, support a possible role of prostacyclin in colon carcinogenesis and are consistent with the findings of previous studies and proposed biological mechanisms (24). In addition, a recent study showed that tissue samples from colon cancer and adenoma cases had hypermethylated PGIS promoter regions compared with normal colon tissue, further supporting the hypothesis that PGIS may play a role in cancer prevention (53).

Our results suggest that the risk reduction afforded by NSAID use varies by PGIS genotype. Specifically, we observed that only individuals with at least one wild-type allele showed a reduced risk with regular NSAID use. This may be an important observation pharmacogenetically because it is an indication that not all individuals benefit from regular NSAID use. Our preliminary finding of an increased risk of adenoma and hyperplastic polyps among those with the <6/<6 genotype who used aspirin or other NSAIDs warrants further investigation.

NSAID pharmacogenetics is complex and seems to involve central enzymes in prostaglandin synthesis (6, 7) as well as the metabolism of NSAIDs (47). In light of recent concerns of toxicity associated with COX-2-specific inhibitors, genetic studies may be important to predict who is more likely to benefit from COX-2-specific inhibitor use and who is more prone to cardiovascular side effects.

To our knowledge, this is the first study of the ALOX5 VNTR polymorphism in relation to risk of colorectal neoplasia. We hypothesized that fewer repeats would be associated with decreased risk of colorectal polyps because fewer repeats have been associated with lower gene expression and ALOX5 has procarcinogenic properties (27, 39, 40). Although not statistically significant, our findings are consistent with this hypothesis.

One other group has evaluated the ALOX5 –1700 G>A polymorphism in relation to colon cancer risk, reporting that, among Caucasians, both the GA and AA genotypes were associated with a decreased risk of colon cancer, although this was not statistically significant among those with the AA genotype (8). We did not observe these patterns. Our study provided some evidence that the effects of regular NSAID use may differ by ALOX5 genotype; however, several of the categories were quite small and we may not have had adequate statistical power to detect a true association.

We found evidence that the association with the ALOX5 –1700 G>A polymorphism may differ by COX-2 –765 G>C genotype. Both ALOX5 and COX-2 use arachidonic acid and an interaction due to "substrate shunting" is possible. The COX-2 –765 G>C polymorphism is associated with decreased gene expression (48, 54). Our findings suggest that a comprehensive analysis of genetic variability in this pathway in relation to colorectal neoplasia is warranted.

For comparison, we performed both genotype-based and allele-based analyses for the PGIS and ALOX5 repeat polymorphisms. Whereas a genotype corresponds to the biological entity of the cell, containing two chromosomes, allele-based analyses are increasingly used in haplotype analyses (e.g., the effects of one haplotype are explored without taking the coexisting second haplotype into account). Our results for the PGIS promoter polymorphism illustrate that risk patterns are similar regardless of which approach is used. However, the genotype-based analysis reveals much stronger increases in risk for individuals who carry fewer than 6 repeats on both alleles (<6R/<6R, OR, 1.90; 95% CI, 1.09-3.30) than does the allele-based analysis (OR, 1.30 for 4 repeats; OR, 1.19 for 5 repeats). This suggests that an allele-based approach may fail to fully capture the biological significance of two risk alleles within one cell and that associations may be diluted due to a mixing of effects. The effect of one allele is likely to depend on the characteristics of the second allele of the cell and only a genotype-based approach can capture this information.

One limitation of this study is that the relatively small number of cases with hyperplastic polyps reduced the statistical power to detect associations, especially in stratified analyses. In general, the patterns observed in the hyperplastic polyps agree with the patterns observed among the adenomas. Larger sample sizes would detect potential risk differences in this group with more precision.

Further, the promoter polymorphism we have investigated in this study is not the only identified genetic variant in PGIS. One common synonymous single-nucleotide polymorphism (R373R) and six rare coding mutations have been reported (37, 55). However, these rare mutations had minor allele frequencies of <1%. We chose to use the promoter polymorphism because it has functional relevance, has been associated with other diseases, and is the best characterized of the known PGIS mutations.

Similarly, there are several known polymorphisms in ALOX5, including three synonymous coding single-nucleotide polymorphisms (T7T, T90T, and P576P) and one nonsynonymous coding single-nucleotide polymorphism (E254K; refs. 8, 39). We focused our analyses on ALOX5 polymorphisms likely to have functional effect. Another promoter single-nucleotide polymorphism, –1753 G>A, is known to be in tight linkage disequilibrium with –1700 G>A and has also been associated with a decreased risk of colon cancer (8). Due to the linkage disequilibrium between these two single-nucleotide polymorphisms, the evaluation of either one should be sufficient.

In summary, results from the present study suggest that genetic variability in PGIS alters risk of colorectal polyps; the increased risks observed with fewer repeats are consistent with a cancer-preventive role of prostacyclin. In addition, risks associated with NSAID use differed by PGIS genotype. This result could have pharmacologic implications, indicating that there are genetically defined subgroups that are more likely to benefit from NSAID chemoprevention, a finding that is consistent with our past reports (6, 7, 47). Both PGIS and ALOX5 may interact with COX-2, indicating that the aggregation of genetic variation in eicosanoid synthesis may be relevant for colorectal neoplasia. Finally, our results emphasize the necessity to go beyond an allele-based approach and consider genotypes (e.g., the combination of two alleles) to better define risk patterns in studies of molecular epidemiology.


   Acknowledgments
 
We thank Dr. Roberd Bostick and Lisa Fosdick for their contributions to the initial establishment of the study, Linda Massey for her assistance with the figures, and Drs. Richard Kulmacz and Lee-Ho Wang for their excellent comments on the manuscript.


   Footnotes
 
Grant support: NIH grants R01 CA 89445 and R01 CA 59045.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/17/05; revised 12/14/05; accepted 1/11/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003;17:1986–95.[Abstract/Free Full Text]
  2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871–5.[Abstract/Free Full Text]
  3. Bennett A, Tacca MD, Stamford IF, et al. Prostaglandins from tumours of human large bowel. Br J Cancer 1977;35:881–4.[Medline]
  4. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518–23.[Medline]
  5. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;35:675–8.[Abstract/Free Full Text]
  6. Ulrich CM, Bigler J, Sparks R, et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004;13:889–93.[Abstract/Free Full Text]
  7. Ulrich CM, Whitton J, Yu JH, et al. PTGS2 (COX-2) –765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616–9.[Abstract/Free Full Text]
  8. Goodman JE, Bowman ED, Chanock SJ, et al. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004;25:2467–72.[Abstract/Free Full Text]
  9. Koh WP, Yuan JM, Van Den Berg D, et al. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br J Cancer 2004;90:1760–4.[Medline]
  10. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305–15.[Abstract/Free Full Text]
  11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–5.[Medline]
  12. Giovannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999;53:303–8.[CrossRef][Medline]
  13. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609–20.[Abstract/Free Full Text]
  14. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–90.[Abstract/Free Full Text]
  15. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–9.[Abstract/Free Full Text]
  16. Vane JR. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. J Endocrinol 1982;95:3–43P.
  17. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 1981;212:1270–2.[Abstract/Free Full Text]
  18. Schirner M, Schneider MR. Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth. Cancer Detect Prev 1997;21:44–50.[Medline]
  19. Lim H, Dey SK. A novel pathway of prostacyclin signaling—hanging out with nuclear receptors. Endocrinology 2002;143:3207–10.[Abstract/Free Full Text]
  20. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954–7.[Abstract/Free Full Text]
  21. Miyata A, Hara S, Yokoyama C, et al. Molecular cloning and expression of human prostacyclin synthase. Biochem Biophys Res Commun 1994;200:1728–34.[CrossRef][Medline]
  22. Pradono P, Tazawa R, Maemondo M, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002;62:63–6.[Abstract/Free Full Text]
  23. Yoshida N, Yoshikawa T, Nakagawa S, et al. Effect of shear stress and a stable prostaglandin I2 analogue on adhesive interactions of colon cancer cells and endothelial cells. Clin Exp Immunol 1999;117:430–4.[CrossRef][Medline]
  24. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002;62:734–40.[Abstract/Free Full Text]
  25. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004;64:5897–904.[Abstract/Free Full Text]
  26. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604–10.[Abstract/Free Full Text]
  27. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307–12.[Abstract/Free Full Text]
  28. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2002;68–9:211–34.
  29. Tong WG, Ding XZ, Witt RC, et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002;1:929–35.[Abstract/Free Full Text]
  30. Nielsen CK, Ohd JF, Wikstrom K, et al. The leukotriene receptor CysLT1 and 5-lipoxygenase are up-regulated in colon cancer. Adv Exp Med Biol 2003;525:201–4.[Medline]
  31. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005;26:785–91.[Abstract/Free Full Text]
  32. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007–9.[Free Full Text]
  33. Anderson KM, Seed T, Vos M, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998;37:161–73.[CrossRef][Medline]
  34. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002;161:421–8.[Abstract/Free Full Text]
  35. Ye YN, Liu ES, Shin VY, et al. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004;203:179–88.[CrossRef][Medline]
  36. Iwai N, Katsuya T, Ishikawa K, et al. Human prostacyclin synthase gene and hypertension: the Suita Study. Circulation 1999;100:2231–6.[Abstract/Free Full Text]
  37. Chevalier D, Cauffiez C, Bernard C, et al. Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1). Hum Genet 2001;108:148–55.[CrossRef][Medline]
  38. Nakayama T, Soma M, Rehemudula D, et al. Association of 5' upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 2000;13:1263–7.[CrossRef][Medline]
  39. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130–7.[Medline]
  40. Silverman ES, Drazen JM. Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications. Am J Respir Crit Care Med 2000;161:S77–80.[Free Full Text]
  41. Sheng H, Shao J, Hooton EB, et al. Cyclooxygenase-2 induction and transforming growth factor ß growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997;8:463–70.[Abstract]
  42. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5:779–84.[Abstract]
  43. O'Brien M, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990;98:371–9.[Medline]
  44. Sayers I, Barton S, Rorke S, et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 2003;33:1103–10.[CrossRef][Medline]
  45. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999;8:659–68.[Abstract/Free Full Text]
  46. Morimoto LM, Newcomb PA, Ulrich CM, et al. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev 2002;11:1012–8.[Abstract/Free Full Text]
  47. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566–9.[Abstract/Free Full Text]
  48. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.[comment]. Arterioscler Thromb Vasc Biol 2002;22:1631–6.[Abstract/Free Full Text]
  49. Ulrich CM, Bigler J, Sibert J, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002;20:409–10.[Medline]
  50. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factor ß1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610–5.[Abstract/Free Full Text]
  51. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006;130:55–64.[CrossRef][Medline]
  52. Sparks R, Bigler J, Sibert JG, et al. TGFß1 polymorphism (L10P) and risk of colorectal adenomatous and hyperplastic polyps. Int J Epidemiol 2004;33:955–61.[Abstract/Free Full Text]
  53. Frigola J, Munoz M, Clark SJ, et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene 2005;24:7320–6.[CrossRef][Medline]
  54. Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221–8.[Abstract/Free Full Text]
  55. Nakayama T, Soma M, Rahmutula D, et al. Nonsense mutation of prostacyclin synthase gene in a family. Lancet 1997;349:1887–8.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. Andreotti, J. Chen, Y.-T. Gao, A. Rashid, B. E. Chen, P. Rosenberg, L. C. Sakoda, J. Deng, M.-C. Shen, B.-S. Wang, et al.
Polymorphisms of Genes in the Lipid Metabolism Pathway and Risk of Biliary Tract Cancers and Stones: A Population-Based Case-Control Study in Shanghai, China
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 525 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. L. Neuhouser, M. J. Barnett, A. R. Kristal, C. B. Ambrosone, I. King, M. Thornquist, and G. Goodman
(n-6) PUFA Increase and Dairy Foods Decrease Prostate Cancer Risk in Heavy Smokers
J. Nutr., July 1, 2007; 137(7): 1821 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu, et al.
Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer
Carcinogenesis, June 1, 2007; 28(6): 1197 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, R. J. Kulmacz, J. D. Potter, and C. M. Ulrich
Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps
Carcinogenesis, June 1, 2007; 28(6): 1259 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. L. R. Barry, J. A. Baron, S. Bhat, M. V. Grau, C. A. Burke, R. S. Sandler, D. J. Ahnen, R. W. Haile, and T. G. O'Brien
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
J Natl Cancer Inst, October 18, 2006; 98(20): 1494 - 1500.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poole, E. M.
Right arrow Articles by Ulrich, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poole, E. M.
Right arrow Articles by Ulrich, C. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online